Related Experiment Video
Updated: Apr 27, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Management of dyslipidemia in patients with human immunodeficiency virus
1Swedish Medical Center, Seattle, WA.
Insights
Dyslipidemia is common in people with human immunodeficiency virus (HIV). Managing lipid levels is crucial for reducing cardiovascular risk in HIV patients on combination antiretroviral therapy (ART).
Area of Science:
- Internal Medicine
- Cardiology
- Infectious Diseases
Background:
- Dyslipidemias are prevalent in patients with human immunodeficiency virus (HIV).
- Combination antiretroviral therapy (ART) has improved HIV management, leading to increased longevity.
- Cardiovascular diseases are now a leading cause of mortality in the HIV-infected population.
Purpose of the Study:
- To review the management of dyslipidemia in HIV-infected individuals.
- To highlight the importance of optimizing lipid parameters for cardiovascular risk reduction in this population.
Main Methods:
- Literature review of studies on dyslipidemia management in HIV patients on ART.
Main Results:
- Dyslipidemia is a significant concern in HIV patients, particularly those on ART.
- Effective management of lipid profiles is essential for mitigating cardiovascular risk.
Conclusions:
- Optimizing fasting lipid parameters is a key strategy in reducing cardiovascular risk for HIV-infected individuals.
- This review provides insights into managing dyslipidemia within the context of combination ART.
Abstract:
Dyslipidemias are more common in the patient population with human immunodeficiency virus (HIV). Combination antiretroviral therapy (ART) has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV disease into a chronic, manageable condition. As a result, non-AIDS-related illnesses, including cardiovascular diseases, are now the leading causes of death in the HIV-infected population. Optimizing fasting lipid parameters plays an important role in reducing cardiovascular risk in this population. This review focuses on the management of dyslipidemia in HIV-infected individuals treated with combination ART.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Retrovirus Life Cycles
Sexually Transmitted Infections
Angina IV: Management
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

